Satoshi Yuki
Overview
Explore the profile of Satoshi Yuki including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
111
Citations
1065
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Imai M, Nakamura Y, Shin S, Okamoto W, Kato T, Esaki T, et al.
JCO Precis Oncol
. 2025 Jan;
9():e2400385.
PMID: 39823559
Purpose: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have shown promise in treating -amplified metastatic colorectal cancer (mCRC). Identifying optimal biomarkers for treatment decisions remains challenging. This study explores...
2.
Asahara N, Ebisu H, Yuki S, Fujita R, Kojima S
Biomed Pharmacother
. 2024 Dec;
182():117792.
PMID: 39733589
The anti-atherosclerotic effects of high-density lipoprotein (HDL) prevent the onset of cerebral infarction and provide cerebroprotective effects against ischemia-reperfusion injury. These inhibitory effects have been attributed to its antioxidant, anti-inflammatory,...
3.
Hashimoto T, Nakamura Y, Komatsu Y, Yuki S, Takahashi N, Okano N, et al.
BJC Rep
. 2024 Nov;
2(1):54.
PMID: 39516322
Background: While advanced gastrointestinal stromal tumors (GISTs) are primarily treated with tyrosine kinase inhibitors (TKIs), acquired resistance from specific mutations in KIT or PDGFRA frequently occurs. We aimed to assess...
4.
Nakamura Y, Ozaki H, Ueno M, Komatsu Y, Yuki S, Esaki T, et al.
Nat Med
. 2024 Sep;
31(1):165-175.
PMID: 39284955
Although comprehensive genomic profiling has become standard in oncology for advanced solid tumors, the full potential of circulating tumor DNA (ctDNA)-based profiling in capturing tumor heterogeneity and guiding therapy selection...
5.
Iida N, Imai M, Okamoto W, Kato T, Esaki T, Kato K, et al.
Clin Cancer Res
. 2024 Aug;
30(18):4167-4178.
PMID: 39163021
Purpose: HER2-targeted therapies in ERBB2-amplified metastatic colorectal cancer (mCRC) are effective; however, a notable portion of patients do not respond to treatment, and secondary resistance occurs in most patients receiving...
6.
Nakatsumi H, Komatsu Y, Harada K, Kawamoto Y, Yuki S, Sawada K, et al.
Int J Cancer
. 2024 Aug;
155(12):2223-2231.
PMID: 39143041
Aflibercept (AFL) plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer (mCRC). However, there is limited evidence on the efficacy and safety of AFL plus FOLFIRI previously...
7.
Hashimoto T, Nakamura Y, Fujisawa T, Imai M, Shibuki T, Iida N, et al.
Cancer Discov
. 2024 Jul;
14(11):2243-2261.
PMID: 39023403
The SCRUM-Japan MONSTAR-SCREEN consortium is a nationwide molecular profiling project employing artificial intelligence-driven multiomics analyses for patients with advanced malignancies, aiming to develop novel therapeutics and diagnostics and deliver effective...
8.
Tsukada Y, Bando H, Inamori K, Wakabayashi M, Togashi Y, Koyama S, et al.
Br J Cancer
. 2024 Jun;
131(2):283-289.
PMID: 38834744
Background: Preoperative chemoradiotherapy (CRT) followed by surgery is the standard treatment for locally advanced rectal cancer (LARC). We reported the short-term outcomes of the VOLTAGE trial that investigated the safety...
9.
Ueda A, Yuki S, Ando T, Hosokawa A, Nakada N, Kito Y, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473233
Currently, no established marker exists for predicting peritoneal metastasis progression during chemotherapy, although they are major interruptive factors in sequential chemotherapy in patients with advanced gastric cancer (AGC). This multicenter...
10.
Yuki S, Yamazaki K, Sunakawa Y, Taniguchi H, Bando H, Shiozawa M, et al.
Clin Colorectal Cancer
. 2024 Feb;
23(2):147-159.e7.
PMID: 38331650
Background: The significance of angiogenic factors as predictors of second-line (2L) chemotherapy efficacy when combined with angiogenesis inhibitors for metastatic colorectal cancer (mCRC) remains unestablished. Patients And Methods: In this...